Katsiki Niki, Athyros Vasilios G, Karagiannis Asterios, Mikhailidis Dimitri P
Department of Clinical Biochemistry, Royal Free Hospital Campus, University College Medical School, University College London (UCL), Pond Street, London NW3 2QG, UK.
Curr Pharm Des. 2016;22(18):2723-5. doi: 10.2174/1381612822666160125114626.
In a review [1] published in this journal in 2014 we updated the role of statin treatment in patients with type 2 diabetes mellitus (T2DM). This is an important topic because the prevalence of T2DM is increasing and this disease is associated with a high risk of cardiovascular disease (CVD) as well as microvascular complications [1]. The relationship between T2DM and statins is further complicated since these drugs can cause new onset diabetes (NOD) although there is an overall benefit in terms of preventing vascular events [1, 2]. The cost implications of T2DM in terms of quality of life as well as providing healthcare are obvious. This is a brief update of our earlier review [1] based on recently published data.
在2014年发表于本杂志的一篇综述[1]中，我们更新了他汀类药物治疗2型糖尿病（T2DM）患者的作用。这是一个重要的话题，因为T2DM的患病率正在上升，且这种疾病与心血管疾病（CVD）以及微血管并发症的高风险相关[1]。T2DM与他汀类药物之间的关系更加复杂，因为这些药物可导致新发糖尿病（NOD），尽管在预防血管事件方面有总体益处[1,2]。T2DM在生活质量以及提供医疗保健方面的成本影响是显而易见的。这是基于最近发表的数据对我们早期综述[1]的简要更新。
